Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ambrisentan

Ambrisentan Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pulmonary arterial hypertension (PAH). It has a low potential for drug-drug interactions and requires only once-daily administration. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Loading next page...
 
/lp/springer-journals/ambrisentan-0Ivmk0RiHJ

References (59)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/11207340-000000000-00000
pmid
21623643
Publisher site
See Article on Publisher Site

Abstract

Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pulmonary arterial hypertension (PAH). It has a low potential for drug-drug interactions and requires only once-daily administration.

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 17, 2012

There are no references for this article.